RxDoctor Payments Data

John Plastaras, MD

Radiation Oncology · Philadelphia, PANPI 1720144512

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (47.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by Ion Beam Applications S.A. at 53.3% of the total.

$3,146in general payments, 2019–2025

Across 6 payments — averaging $524.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ion Beam Applications S.A.$2K
  • Siemens Medical Solutions USA, Inc.$1K
  • IBA Proton Therapy, Inc.$66
  • Novocure Inc.$27
$535,256in research payments, 2019–2025

Across 4 payments — averaging $133,814 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$535K

What the payments were for

  • Consulting fees$1,35043%
  • Speaking & faculty fees$1,50048%
  • Food & beverage$2969%

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ion Beam Applications S.A.2$1,677
Siemens Medical Solutions USA, Inc.2$1,376
IBA Proton Therapy, Inc.1$66
Novocure Inc.1$27

How this compares

$3,146 in reported general payments places this provider in the 80th percentile of 339 radiation oncology providers in Pennsylvania.

See all radiation oncology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$136,342
Medicare patients
422
Services billed
1,643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other radiation oncology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →